Kalorama Information notes 4 trends in monoclonal antibodies (mAbs) – large protein molecules produced by white blood cells that seek out and destroy harmful foreign substances – topped $100 billion in 2017, according to Kalorama Information What’s Trending in Monoclonal Antibodies, examines the several types of monoclonal antibodies on the market and in development, looking at the mAbs market by structure, by target, and by indication.
- Humanized mAbs Grow: Advancements in human and humanized monoclonal antibodies will be the major areas of development and growth through 2022. Humanized mAbs will outpace all other structure types with compound annual growth of 13.5%. More than $20 billion in revenues will be generated from new approvals in humanized mAbs over the forecast.
- Watch for growth from PD-1 and PD-L1 mAbs. These segments will show some of the strongest increases over the forecast. Cancer indications are driving sales in these categories and are expected to maintain pace, increasing at CAGR of 38.4% for PD-1 and 21.5% for PD-L1 from 2017-2022. Interleukin mAbs will also enjoy strong adoption. More than $25 billion will come from developments and approvals between 2018 and 2022.
- Neuro mAbs a Particular Focus: Steady growth is expected from oncology and autoimmune disease categories, as expected. But new growth is projected in the neurological segment with many mAb development programs moving froward in the area of Alzheimer’s disease.
- United States First: The U.S. is the strongest mAb market with 56% market share and expected to maintain growth, accounting for 57% of the market in 2022, or $97 billion, an increase of 11.6%.
Further, the report discusses the several factors contributing to the strong growth of the monoclonal antibodies market. Company profiles of the major participants in the mAbs market are provided as well. What’s Trending in Monoclonal Antibodies (Markets by Structure, by Target, and by Indication) can be found at: https://www.kaloramainformation.com/Trending-Monoclonal-Antibodies-Structure-Target-Indication-11440829/.